OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
OKYO Pharma and SolarMax Technology are set to feature on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, August 24, at 7 p.m. ET. The show, available in an estimated 73 million U.S. homes, will air exclusive interviews with the CEOs of both companies.
OKYO Pharma (Nasdaq: OKYO), a clinical-stage biopharmaceutical company, is developing innovative therapies for Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP). Their lead candidate, OK-101, showed promising results in a recent Phase 2 trial for DED, demonstrating improvements in symptoms and signs within 15 days.
SolarMax Technology (Nasdaq: SMXT), founded in 2008, has completed over 15,000 solar installations. The company is expanding its commercial solar development services in the U.S. market, with recent large-scale projects announced in Las Vegas and San Jose.
OKYO Pharma e SolarMax Technology saranno protagonisti dello spettacolo RedChip Small Stocks, Big Money™ su Bloomberg TV questo sabato, 24 agosto, alle 19:00 ET. Lo show, disponibile in circa 73 milioni di case negli Stati Uniti, presenterà interviste esclusive con i CEO di entrambe le aziende.
OKYO Pharma (Nasdaq: OKYO), una compagnia biofarmaceutica in fase clinica, sta sviluppando terapie innovative per la Malattia da Occhio Secco (DED) e il Dolore Corneale Neuropatico (NCP). Il loro candidato principale, OK-101, ha mostrato risultati promettenti in un recente studio di Fase 2 per DED, dimostrando miglioramenti nei sintomi e nei segni entro 15 giorni.
SolarMax Technology (Nasdaq: SMXT), fondata nel 2008, ha completato oltre 15.000 installazioni solari. L'azienda sta ampliando i suoi servizi di sviluppo solare commerciale nel mercato statunitense, con recenti progetti su larga scala annunciati a Las Vegas e San Jose.
OKYO Pharma y SolarMax Technology aparecerán en el programa RedChip Small Stocks, Big Money™ en Bloomberg TV este sábado 24 de agosto a las 7 p.m. ET. El show, que está disponible en aproximadamente 73 millones de hogares en EE.UU., presentará entrevistas exclusivas con los CEO de ambas compañías.
OKYO Pharma (Nasdaq: OKYO), una empresa biofarmacéutica en etapa clínica, está desarrollando terapias innovadoras para la Enfermedad del Ojo Seco (DED) y el Dolor Corneal Neuropático (NCP). Su candidato principal, OK-101, mostró resultados prometedores en un reciente ensayo de Fase 2 para DED, demostrando mejoras en los síntomas y signos en 15 días.
SolarMax Technology (Nasdaq: SMXT), fundada en 2008, ha completado más de 15,000 instalaciones solares. La empresa está ampliando sus servicios de desarrollo solar comercial en el mercado de EE.UU., con recientes proyectos a gran escala anunciados en Las Vegas y San José.
OKYO Pharma와 SolarMax Technology가 이번 토요일, 8월 24일 오후 7시 ET에 Bloomberg TV의 RedChip Small Stocks, Big Money™ 프로그램에 출연합니다. 이 프로그램은 약 7300만 가구에서 시청할 수 있으며, 두 회사 CEO의 독점 인터뷰를 방송할 예정입니다.
OKYO Pharma (Nasdaq: OKYO)는 임상 단계에 있는 생명공학 회사로, 건성 안질환 (DED) 및 신경병성 각막 통증 (NCP)에 대한 혁신적인 치료법을 개발하고 있습니다. 이들의 대표 후보인 OK-101은 DED에 대한 최근 2상 임상시험에서 증상 및 징후에서 개선 효과를 보이며 15일 이내에 유망한 결과를 나타냈습니다.
SolarMax Technology (Nasdaq: SMXT)는 2008년에 설립되어 15,000건 이상의 태양광 설치를 완료했습니다. 이 회사는 미국 시장에서 상업 태양광 개발 서비스의 확장을 진행하고 있으며, 최근 라스베이거스와 샌호세에서 대규모 프로젝트를 발표했습니다.
OKYO Pharma et SolarMax Technology seront à l'honneur dans l'émission RedChip Small Stocks, Big Money™ sur Bloomberg TV ce samedi 24 août à 19h00 ET. L'émission, disponible dans environ 73 millions de foyers américains, diffusera des interviews exclusives avec les PDG des deux entreprises.
OKYO Pharma (Nasdaq: OKYO), une entreprise bio-pharmaceutique en stade clinique, développe des thérapies innovantes pour la Maladie de l'Œil Sec (DED) et la Douleur Cornéenne Neuropathique (NCP). Leur candidat principal, OK-101, a montré des résultats prometteurs lors d'un récent essai de phase 2 pour le DED, faisant état d'améliorations des symptômes et des signes en 15 jours.
SolarMax Technology (Nasdaq: SMXT), fondée en 2008, a réalisé plus de 15 000 installations solaires. L'entreprise étend ses services de développement solaire commercial sur le marché américain, avec des projets à grande échelle récemment annoncés à Las Vegas et San Jose.
OKYO Pharma und SolarMax Technology werden an diesem Samstag, den 24. August, um 19:00 Uhr ET in der Sendung RedChip Small Stocks, Big Money™ auf Bloomberg TV zu sehen sein. Die Show, die in schätzungsweise 73 Millionen Haushalten in den USA verfügbar ist, wird exklusive Interviews mit den CEOs beider Unternehmen ausstrahlen.
OKYO Pharma (Nasdaq: OKYO), ein biopharmazeutisches Unternehmen in klinischer Entwicklung, arbeitet an innovativen Therapien für Trockenheitssyndrom des Auges (DED) und neuropathische Hornhaut Schmerzen (NCP). Ihr Hauptkandidat, OK-101, zeigte vielversprechende Ergebnisse in einer kürzlich durchgeführten Phase-2-Studie für DED und erwies sich innerhalb von 15 Tagen als wirksam bei der Verbesserung von Symptomen und Befunden.
SolarMax Technology (Nasdaq: SMXT), gegründet 2008, hat über 15.000 Solarinstallationen abgeschlossen. Das Unternehmen erweitert seine kommerziellen Solardienstleistungen im US-Markt und hat kürzlich große Projekte in Las Vegas und San Jose angekündigt.
- OKYO's OK-101 showed notable improvements in DED symptoms and signs within 15 days in Phase 2 trial
- OKYO has patent protection for OK-101 through at least 2039
- SolarMax has completed over 15,000 solar installations since 2008
- SolarMax announced large-scale commercial solar projects in Las Vegas and San Jose in Q3 2025
- None.
ORLANDO, FL / ACCESSWIRE / August 23, 2024 / RedChip Companies will air interviews with OKYO Pharma Ltd. (Nasdaq:OKYO) and SolarMax Technology, Inc. (Nasdaq:SMXT) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
OKYO Pharma: https://www.redchip.com/assets/access/okyo_access
In an exclusive interview, Gary S. Jacob, PhD, CEO of OKYO Pharma, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. OKYO is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP), two areas with significant unmet medical needs. Leveraging a unique lipid-conjugated chemerin peptide, OKYO's lead candidate, OK-101, is designed to address inflammation and pain more effectively than current treatments. The recent Phase 2 trial for DED demonstrated notable improvements in both symptoms and signs within just 15 days, with a favorable safety profile and no drug-related serious adverse events. Moreover, OK-101 also offers a significant opportunity to treat the ocular disease called NCP, with no FDA approved drug to treat patients suffering from this acute, chronic, ocular condition. OKYO's robust patent protection through at least 2039, plus an experienced management team, with proven success in clinical development thru FDA approval, underscore its strong positioning for future growth in ophthalmology therapeutics.
David Hsu, CEO of SolarMax, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Founded in 2008 and based in California, SolarMax has successfully completed over 15,000 installations. Its foray into the Chinese market, which began in 2016 and reached peak annual sales of
About OKYO
OKYO Pharma Limited (NASDAQ:OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
About SolarMax Technology
SolarMax, based in California and founded in 2008, is a leader within the solar and renewable energy sector focused on making sustainable energy both accessible and affordable. SolarMax has established a strong presence in the California and began operations in China in 2016. SolarMax is looking to generate robust growth with strategic initiatives that aim to scale commercial solar development services and LED lighting solutions in the US while expanding its residential solar operations. For more information, visit www.solarmaxtech.com.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
--END--
SOURCE: RedChip
View the original press release on accesswire.com
FAQ
When will OKYO Pharma and SolarMax Technology interviews air on Bloomberg TV?
What are the main therapeutic areas OKYO Pharma (OKYO) is focusing on?
What were the results of OKYO Pharma's (OKYO) recent Phase 2 trial for Dry Eye Disease?
How many solar installations has SolarMax Technology (SMXT) completed?
